Clinical Trial

Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness

Study acronym: MicroUSgFLA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 14, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This clinical research study is intended to show that Micro-Ultrasound Guided Focal Laser Ablation (MicroUSgFLA) is a safe procedure that can significantly postpone or eliminate the need for patients with intermediate-Risk prostate cancer (PCa) to undergo a definitive treatment (i.e., Radical Prostatectomy or Radiation Therapy) for their disease.
Trial Details
NCT Number NCT07339943
Lead Sponsor University Health Network, Toronto
Collaborators: Exact Imaging, Clinical Laserthermia Systems AB
Conditions Prostate Cancer (Adenocarcinoma), Low and Intermediate Risk Prostate Cancer
Enrollment 7 participants
Start Date 2025-04-30
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-14